Clinical Research Directory
Browse clinical research sites, groups, and studies.
4 clinical studies listed.
Filters:
Tundra lists 4 Chronic Myeloid Leukemia in Remission clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT04626024
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
Gender: All
Ages: 18 Years - Any
Updated: 2025-12-19
1 state
NCT05413915
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
The aim of this study is to establish if consolidation of imatinib-treated patients in stable DMR through the addition of asciminib, can lead to superior rates of TFR1, compared to imatinib alone in Chronic Phase-Chronic Myelogenous Leukemia patients.
Gender: All
Ages: 18 Years - Any
Updated: 2025-05-21
1 state
NCT06266975
Chronic Kidney Disease Patient in Chronic Myloied Leukemia
To study the Prevalence ,Characteristics and outcome of CKD in patiants with chronic myeloid leukemia .
Gender: All
Ages: 18 Years - 75 Years
Updated: 2024-02-20
NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized study).
Gender: All
Ages: 18 Years - 75 Years
Updated: 2022-10-12